Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. MU
8. HOOD
9. DFTX
10. RGNX

Go back to Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enliven Marketing Technologies Corporation (NASDAQ: ENLV) Delayed: 0.61 -0.01 (1.61%)
Previous Close $0.62    52 Week High $0.94 
Open $0.63    52 Week Low $0.47 
Day High $0.66    P/E N/A 
Day Low $0.59    EPS $-0.11 
Volume 936,591       

Enliven Marketing Technologies Corporation (NASDAQ: ENLV) Delayed: 0.61 -0.01 (1.61%)
Previous Close $0.62    52 Week High $0.94 
Open $0.63    52 Week Low $0.47 
Day High $0.66    P/E N/A 
Day Low $0.59    EPS $-0.11 
Volume 936,591